Search results
Jasper Therapeutics targets asthma in new Phase 1b/2a study By Investing.com
Investing.com· 7 hours agoThis study aims to explore the drug's potential to deplete mast cells, which are known to play a key...
Questor: Investors are undervaluing this landscaping supplier
The Telegraph via Yahoo Finance· 6 hours agoMarshalls’ full-year results, published in March, contained both a dividend cut for 2023 and a...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 7 days agoMay 7, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune ...
It's Not in Your Head: Doctors Say Allergy Season Is Getting Worse Every Year
Good Housekeeping via AOL· 3 days agoAllergies are a chronic condition where your immune system reacts to a typically harmless substance,...
Noxopharm scales up production of lupus drug SOF-SKN™ to GLP standards
Proactive Investors· 1 hour agoNoxopharm Ltd (ASX:NOX, OTC:NOXOF) has reached a major drug development milestone in scaling up...
Biking revealed to be associated with less knee pain later in life
Medical Xpress· 5 hours agoA study published in Medicine & Science in Sports & Exercise reveals that people who participated in...
Biotest AG: Annual General Meeting Approves Dividend Distribution
NewMediaWire via Yahoo Finance· 6 days agoDistribution of EUR 0.04 per preference share for each of the years 2023 and 2022 Broad majority in...
Learn About How Xolair can Protect Against Food Allergies
1011 News· 6 days agoThe following content is created on behalf of Allergy, Asthma, and Immunology and does not reflect...
Earnings call: Nektar Therapeutics optimistic on REZPEG and pipeline progress
Investing.com· 4 days agoNektar Therapeutics (NASDAQ: NKTR ) reported a productive first quarter of 2024, focusing on their ...
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
Guru Focus· 3 days agoThe biopharmaceutical company, known for its innovative approach in immunology and oncology, reported a net loss of $36.8 million, or $0.19 per share, aligning with analyst ...